ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2022 Congress
    • ISTH 2021 Congress
    • ISTH 2020 Congress
  • Resources
  • Search

Cytokine profile of patients with Acquired Hemophilia A (AHA) in a longitudinal study

J. Frade-Guanaes1, A. Racanelli1, L. Siqueira1, C. Costa-Lima1, S. Medina1, N. Foschi1, L. De Lima1, A. Francisco1, M. Colella1, S. Montalvão2, G. Yamaguti-Hayakawa1, M. Ozelo1

1Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of Campinas, Campinas, Sao Paulo, Brazil, 22Hemostasis and Thrombosis Laboratory, Hematology and Hemotherapy Center, University of Campinas (UNICAMP), Campinas, Sao Paulo, Brazil

Abstract Number: OC 63.5

Meeting: ISTH 2022 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Acquired Hemorrhagic Coagulation Disorders

Background: Acquired Hemophilia A (AHA) is an autoimmune disease caused by the production of autoantibodies against factor VIII. There is limited data about the pathophysiology of the disease, including T and B cells response.

Aims: To determine the cytokine expression through T and B cells activation in a longitudinal evaluation of patients with AHA.

Methods: This study included 18 patients diagnosed with AHA from a single center. Peripheral blood mononuclear cells were isolated before immunosuppressive therapy (IST), after achieving complete remission, and at relapse/failure. Cells were cultivated with RPMI-1640 medium, with 7.5×105 cells/well in a 48-well plate. After 24h, cells were stimulated with full-length recombinant FVIII concentrate (rFVIII). After incubation for 24h, cells were analyzed by flow cytometry (FACS).

Results: IST consisted of prednisone with cyclophosphamide (72.2%), only cyclophosphamide (11.1%) and, rituximab as second-line therapy (16.7%). 50% of patients (n=9) achieved complete remission, and 27.8% (n=5) were considered as failure (2) or relapse (3). Three patients are still under initial follow-up, and one patient died and was censured for the longitudinal analysis (table 1). We observed a significant increase in the production of CD4 cytokine subsets in both responding and non-responding (failure/relapse) patients at baseline when compared with healthy individuals. This difference was not observed when patients achieved remission. Also, we observed increased production of Th17 [IL-17A (P= 0.0002), IL-21 (P=0.007), TGF-b (P=0.04)], Th2 [IL-4 (P= 0.004)] and Th1 cytokines [TNF-a (P=0.006), IFN-γ (P=0.001)] between all AHA at baseline and controls. Interestingly, as we previously reported for BAFF (B-cell activating factor), baseline levels of IFN-γ were markedly increased in non-responding patients when compared to patients with sustained complete remission (figure 1).

Conclusion(s): Our findings suggest that BAFF levels in B cells and IFN- γ in T cells at the diagnosis are potential biomarkers for AHA prognosis and treatment response.

To cite this abstract in AMA style:

Frade-Guanaes J, Racanelli A, Siqueira L, Costa-Lima C, Medina S, Foschi N, De Lima L, Francisco A, Colella M, Montalvão S, Yamaguti-Hayakawa G, Ozelo M. Cytokine profile of patients with Acquired Hemophilia A (AHA) in a longitudinal study [abstract]. https://abstracts.isth.org/abstract/cytokine-profile-of-patients-with-acquired-hemophilia-a-aha-in-a-longitudinal-study/. Accessed September 27, 2023.

« Back to ISTH 2022 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/cytokine-profile-of-patients-with-acquired-hemophilia-a-aha-in-a-longitudinal-study/

Simple Search

Supported By:

Takeda logo

ISTH 2022 Congress site

Visit the official web site for the ISTH 2022 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2023 John Wiley & Sons, Inc. All Rights Reserved.
Wiley